Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Short-term Investments: 2019-2024

Historic Short-term Investments for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $368.5 million.

  • Kymera Therapeutics' Short-term Investments fell 10.59% to $392.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.7 million, marking a year-over-year decrease of 10.59%. This contributed to the annual value of $368.5 million for FY2024, which is 39.10% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Short-term Investments of $368.5 million as of FY2024, which was up 39.10% from $264.9 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Short-term Investments ranged from a high of $394.4 million in FY2021 and a low of $264.9 million during FY2023.
  • For the 3-year period, Kymera Therapeutics' Short-term Investments averaged around $324.1 million, with its median value being $338.8 million (2022).
  • As far as peak fluctuations go, Kymera Therapeutics' Short-term Investments skyrocketed by 1,563.52% in 2020, and later fell by 21.80% in 2023.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Short-term Investments stood at $265.2 million in 2020, then surged by 48.73% to $394.4 million in 2021, then decreased by 14.11% to $338.8 million in 2022, then decreased by 21.80% to $264.9 million in 2023, then skyrocketed by 39.10% to $368.5 million in 2024.